Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImperial Innovations Group Regulatory News (IVO)

  • There is currently no data for IVO

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Notice of cancellation of admission to AIM

13 Nov 2017 07:00

RNS Number : 2415W
Touchstone Innovations PLC
13 November 2017
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION

13 November 2017

Touchstone Innovations plc

 

Notice of cancellation of admission to trading on AIM

 

Further to the announcement released on 18 October 2017 by IP Group plc ("IP Group") declaring the IP Group offer (the "Offer") wholly unconditional in all respects, Touchstone Innovations plc ("Touchstone" or the "Company") notifies its shareholders that, at the request of IP Group, an application has been made to London Stock Exchange plc to cancel the trading facility in the ordinary shares in the capital of the Company ("Ordinary Shares") on AIM with effect from 7:00am on 11 December 2017.

The cancellation of trading in the Ordinary Shares will significantly reduce the liquidity and marketability of any Ordinary Shares and, as previously stated, the Board of Touchstone recommends that Touchstone shareholders who have not yet accepted the Offer now do so promptly.

Those Touchstone shareholders who accept the Offer will receive their new shares in IP Group as consideration for their Touchstone shares at an earlier date than they would as part of the compulsory acquisition procedure.

IP Group has announced that the Offer will remain open until further notice and that not less than 14 calendar days' notice will be given in respect of the closure of the Offer.

If you are a Touchstone shareholder and in any doubt as to the action you should take, you are recommended to seek your own financial advice immediately from your stockbroker, bank manager, solicitor, accountant, fund manager or other appropriate independent financial adviser authorised under the Financial Services and Markets Act 2000, as amended if you are resident in the United Kingdom or, if not, from another appropriately authorised independent financial adviser.

For further information contact:

Touchstone Innovations plc

020 3053 8834

Russ Cummings, Chief Executive Officer

William Rayner, General Counsel and Company Secretary

Jon Davies, Director of Communications

Instinctif Partners

020 7457 2020

Adrian Duffield/Mel Toyne-Sewell/Chantal Woolcock

J.P. Morgan Cazenove (Nominated adviser)

020 7742 4000

Michael Wentworth-Stanley/Alec Pratt

RBC Capital Markets (Joint Corporate Broker)

020 7653 4000

Marcus Jackson

 

Further Information

J.P. Morgan Limited, which conducts its UK investment banking business as J.P. Morgan Cazenove ("J.P. Morgan Cazenove"), is authorised and regulated in the United Kingdom by the Financial Conduct Authority. J.P. Morgan Cazenove is acting as financial adviser exclusively for Touchstone Innovations plc and no one else in connection with the matters set out in this announcement and will not regard any other person as its client in relation to the matters in this announcement and will not be responsible to anyone other than Touchstone Innovations plc for providing the protections afforded to clients of J.P. Morgan Cazenove or its affiliates, or for providing advice in relation to any matter referred to herein.

RBC Capital Markets is the business name used by RBC Europe Limited, which is authorised in the United Kingdom by the Prudential Regulation Authority ("PRA") and regulated by the Financial Conduct Authority and the PRA and is a subsidiary of the Royal Bank of Canada. RBC is acting as Corporate Broker to the Company.

 

Ends

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCEAPFEFDSXFFF
Date   Source Headline
28th Jul 20157:01 amRNS£1 million seed investment in Inflowmatix
27th Jul 20157:00 amRNS£3.0 million investment in Concirrus
23rd Jul 20151:35 pmRNSDirectorate Change
14th Jul 20157:00 amRNSFurther £50m loan facility from EIB
2nd Jul 20157:00 amRNS£4.0m funding round in Impression Technologies
1st Jul 20157:00 amRNSFirst subject enrolled in Veryan Medical's study
30th Jun 20157:00 amRNSLeads £3 million investment in Abingdon Health
8th Jun 20151:18 pmRNSDirectorate Change
3rd Jun 20157:00 amRNSInnovations leads £6m funding round in Auspherix
29th May 20157:00 amRNSAppointment of Executive Chairman at Kesios
27th May 20154:05 pmRNSHolding(s) in Company
26th May 20157:01 amRNSDivests its shares of Epigeum
19th May 20157:00 amRNS£25m Series C funding round in PsiOxus
14th May 20157:00 amRNSTopiVert starts Phase I Clinical Trial
30th Apr 20153:48 pmRNSDirector's share purchase
27th Apr 20157:00 amRNSAutifony Therapeutics recruits first trial patient
15th Apr 20157:00 amRNSInnovations leads £5.9m funding round in Yoyo
27th Mar 20157:00 amRNSHalf Yearly Report
24th Mar 20154:40 pmRNSSecond Price Monitoring Extn
24th Mar 20154:35 pmRNSPrice Monitoring Extension
18th Mar 20157:00 amRNSCell Medica granted Orphan Drug designation
13th Mar 201510:07 amRNSEdison publishes research on Imperial Innovations
27th Feb 201511:48 amRNSNotice of Results
19th Feb 20157:00 amRNSCell Medica to commence cell therapy manufacture
14th Jan 201512:13 pmRNS£18 million Series B funding round in Veryan
18th Dec 20147:00 amRNSImperial named UK's top research university
16th Dec 201411:39 amRNSResult of AGM
9th Dec 20142:55 pmRNSGrant of options under SAYE Scheme
26th Nov 20143:41 pmRNSGrant of share options
25th Nov 201410:45 amRNSReplacement Director's share purchase
25th Nov 20147:00 amRNS£50 million Series B funding round in Cell Medica
24th Nov 20144:20 pmRNSDirector's share sale
12th Nov 20147:00 amRNSPosting of Annual Report and Notice of AGM
24th Oct 20147:00 amRNSDirectorate Changes
15th Oct 20147:00 amRNSFinal Results
8th Oct 20147:00 amRNSInnovations invests £1.85m in Kesios Therapeutics
5th Sep 20141:55 pmRNSNotice of Results
13th Aug 201412:43 pmRNSDirector's share sale
15th Jul 20142:08 pmRNSDirectorate Change
7th Jul 20147:14 amRNSPortfolio company Abzena announces offer price
4th Jul 20143:36 pmRNSHolding(s) in Company
23rd Jun 20143:15 pmRNSResults of Placing
23rd Jun 20147:00 amRNSPlacing to raise £150 million
19th Jun 201412:45 pmRNSResult of General Meeting
16th Jun 20147:09 amRNSPortfolio company announces intention to float
12th Jun 20147:00 amRNSImperial Innovations invests £1.5m in Cortexica
10th Jun 20147:00 amRNS£3 million funding round for Featurespace
4th Jun 20147:00 amRNSAutifony receives funding for Phase II trial
2nd Jun 20147:00 amRNSAppointment of non-executive directors
2nd Jun 20147:00 amRNSProposed Placing to raise up to £150 million

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.